nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—Topoisomerase Inhibitors—Epirubicin—thyroid cancer	0.348	0.519	CiPCiCtD
Mitoxantrone—Topoisomerase Inhibitors—Doxorubicin—thyroid cancer	0.322	0.481	CiPCiCtD
Mitoxantrone—TOP2A—Epirubicin—thyroid cancer	0.0454	0.197	CbGbCtD
Mitoxantrone—ABCC1—Vandetanib—thyroid cancer	0.0366	0.159	CbGbCtD
Mitoxantrone—ABCC1—Epirubicin—thyroid cancer	0.0252	0.109	CbGbCtD
Mitoxantrone—ABCG2—Vandetanib—thyroid cancer	0.0245	0.106	CbGbCtD
Mitoxantrone—TOP2A—Doxorubicin—thyroid cancer	0.0241	0.105	CbGbCtD
Mitoxantrone—CYP1B1—Doxorubicin—thyroid cancer	0.0188	0.0816	CbGbCtD
Mitoxantrone—ABCG2—Sorafenib—thyroid cancer	0.0148	0.064	CbGbCtD
Mitoxantrone—ABCC1—Doxorubicin—thyroid cancer	0.0134	0.058	CbGbCtD
Mitoxantrone—ABCG2—Doxorubicin—thyroid cancer	0.00895	0.0388	CbGbCtD
Mitoxantrone—ABCB1—Sorafenib—thyroid cancer	0.00532	0.0231	CbGbCtD
Mitoxantrone—CYP3A4—Vandetanib—thyroid cancer	0.00529	0.0229	CbGbCtD
Mitoxantrone—ABCB1—Doxorubicin—thyroid cancer	0.00323	0.014	CbGbCtD
Mitoxantrone—CYP3A4—Sorafenib—thyroid cancer	0.00319	0.0138	CbGbCtD
Mitoxantrone—CYP3A4—Doxorubicin—thyroid cancer	0.00193	0.00839	CbGbCtD
Mitoxantrone—SLC47A2—head—thyroid cancer	0.000671	0.102	CbGeAlD
Mitoxantrone—PIM1—trachea—thyroid cancer	0.000625	0.0952	CbGeAlD
Mitoxantrone—BTK—thyroid gland—thyroid cancer	0.00057	0.0869	CbGeAlD
Mitoxantrone—TOP2A—Erlotinib—Vandetanib—thyroid cancer	0.000499	0.312	CbGdCrCtD
Mitoxantrone—PIM1—thyroid gland—thyroid cancer	0.000494	0.0753	CbGeAlD
Mitoxantrone—PIM1—head—thyroid cancer	0.000438	0.0668	CbGeAlD
Mitoxantrone—BTK—lymph node—thyroid cancer	0.000354	0.054	CbGeAlD
Mitoxantrone—TOP2A—Afatinib—Vandetanib—thyroid cancer	0.000326	0.204	CbGdCrCtD
Mitoxantrone—PIM1—lymph node—thyroid cancer	0.000307	0.0468	CbGeAlD
Mitoxantrone—TOP2A—thyroid gland—thyroid cancer	0.00029	0.0442	CbGeAlD
Mitoxantrone—TOP2A—Gefitinib—Vandetanib—thyroid cancer	0.000285	0.178	CbGdCrCtD
Mitoxantrone—SLC47A1—thyroid gland—thyroid cancer	0.000265	0.0404	CbGeAlD
Mitoxantrone—ABCG2—saliva-secreting gland—thyroid cancer	0.000237	0.0361	CbGeAlD
Mitoxantrone—SLC47A1—head—thyroid cancer	0.000235	0.0358	CbGeAlD
Mitoxantrone—ABCC1—trachea—thyroid cancer	0.000221	0.0336	CbGeAlD
Mitoxantrone—CYP1B1—thyroid gland—thyroid cancer	0.000194	0.0296	CbGeAlD
Mitoxantrone—TOP2A—lymph node—thyroid cancer	0.00018	0.0274	CbGeAlD
Mitoxantrone—ABCC1—thyroid gland—thyroid cancer	0.000175	0.0266	CbGeAlD
Mitoxantrone—CYP1B1—head—thyroid cancer	0.000172	0.0262	CbGeAlD
Mitoxantrone—SLC47A1—lymph node—thyroid cancer	0.000164	0.0251	CbGeAlD
Mitoxantrone—ABCG2—thyroid gland—thyroid cancer	0.000145	0.022	CbGeAlD
Mitoxantrone—Arrhythmia—Sorafenib—thyroid cancer	0.000134	0.00198	CcSEcCtD
Mitoxantrone—Alopecia—Sorafenib—thyroid cancer	0.000133	0.00196	CcSEcCtD
Mitoxantrone—Fungal infection—Doxorubicin—thyroid cancer	0.000132	0.00196	CcSEcCtD
Mitoxantrone—Erythema—Sorafenib—thyroid cancer	0.000131	0.00193	CcSEcCtD
Mitoxantrone—Necrosis—Doxorubicin—thyroid cancer	0.00013	0.00192	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000129	0.00191	CcSEcCtD
Mitoxantrone—Dysgeusia—Sorafenib—thyroid cancer	0.000128	0.00189	CcSEcCtD
Mitoxantrone—Extravasation—Epirubicin—thyroid cancer	0.000127	0.00187	CcSEcCtD
Mitoxantrone—Amenorrhoea—Epirubicin—thyroid cancer	0.000126	0.00186	CcSEcCtD
Mitoxantrone—CYP2E1—thyroid gland—thyroid cancer	0.000125	0.0191	CbGeAlD
Mitoxantrone—Body temperature increased—Vandetanib—thyroid cancer	0.000125	0.00185	CcSEcCtD
Mitoxantrone—Abdominal pain—Vandetanib—thyroid cancer	0.000125	0.00185	CcSEcCtD
Mitoxantrone—Petechiae—Doxorubicin—thyroid cancer	0.000124	0.00184	CcSEcCtD
Mitoxantrone—Viral infection—Epirubicin—thyroid cancer	0.000122	0.00181	CcSEcCtD
Mitoxantrone—Anaemia—Sorafenib—thyroid cancer	0.000121	0.00178	CcSEcCtD
Mitoxantrone—Hypocalcaemia—Epirubicin—thyroid cancer	0.000121	0.00178	CcSEcCtD
Mitoxantrone—CYP1B1—lymph node—thyroid cancer	0.000121	0.0184	CbGeAlD
Mitoxantrone—Hyperuricaemia—Epirubicin—thyroid cancer	0.000119	0.00176	CcSEcCtD
Mitoxantrone—Extravasation—Doxorubicin—thyroid cancer	0.000117	0.00173	CcSEcCtD
Mitoxantrone—Leukopenia—Sorafenib—thyroid cancer	0.000117	0.00173	CcSEcCtD
Mitoxantrone—Blood bilirubin increased—Epirubicin—thyroid cancer	0.000117	0.00173	CcSEcCtD
Mitoxantrone—Ulcer—Epirubicin—thyroid cancer	0.000117	0.00173	CcSEcCtD
Mitoxantrone—Amenorrhoea—Doxorubicin—thyroid cancer	0.000116	0.00172	CcSEcCtD
Mitoxantrone—Bone pain—Epirubicin—thyroid cancer	0.000115	0.0017	CcSEcCtD
Mitoxantrone—Cough—Sorafenib—thyroid cancer	0.000114	0.00168	CcSEcCtD
Mitoxantrone—Asthenia—Vandetanib—thyroid cancer	0.000113	0.00168	CcSEcCtD
Mitoxantrone—Viral infection—Doxorubicin—thyroid cancer	0.000113	0.00167	CcSEcCtD
Mitoxantrone—Hypertension—Sorafenib—thyroid cancer	0.000113	0.00167	CcSEcCtD
Mitoxantrone—Blood uric acid increased—Epirubicin—thyroid cancer	0.000113	0.00166	CcSEcCtD
Mitoxantrone—Hypocalcaemia—Doxorubicin—thyroid cancer	0.000112	0.00165	CcSEcCtD
Mitoxantrone—Myalgia—Sorafenib—thyroid cancer	0.000111	0.00164	CcSEcCtD
Mitoxantrone—Arthralgia—Sorafenib—thyroid cancer	0.000111	0.00164	CcSEcCtD
Mitoxantrone—CYP2E1—head—thyroid cancer	0.000111	0.0169	CbGeAlD
Mitoxantrone—Hyperuricaemia—Doxorubicin—thyroid cancer	0.00011	0.00163	CcSEcCtD
Mitoxantrone—Hyperkalaemia—Epirubicin—thyroid cancer	0.000109	0.0016	CcSEcCtD
Mitoxantrone—ABCC1—lymph node—thyroid cancer	0.000108	0.0165	CbGeAlD
Mitoxantrone—Diarrhoea—Vandetanib—thyroid cancer	0.000108	0.0016	CcSEcCtD
Mitoxantrone—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.000108	0.0016	CcSEcCtD
Mitoxantrone—Ulcer—Doxorubicin—thyroid cancer	0.000108	0.0016	CcSEcCtD
Mitoxantrone—Bone pain—Doxorubicin—thyroid cancer	0.000107	0.00158	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Sorafenib—thyroid cancer	0.000107	0.00158	CcSEcCtD
Mitoxantrone—Infection—Sorafenib—thyroid cancer	0.000106	0.00157	CcSEcCtD
Mitoxantrone—Shock—Sorafenib—thyroid cancer	0.000105	0.00155	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Sorafenib—thyroid cancer	0.000104	0.00154	CcSEcCtD
Mitoxantrone—Blood urea increased—Epirubicin—thyroid cancer	0.000104	0.00154	CcSEcCtD
Mitoxantrone—Blood uric acid increased—Doxorubicin—thyroid cancer	0.000104	0.00154	CcSEcCtD
Mitoxantrone—Skin disorder—Sorafenib—thyroid cancer	0.000104	0.00153	CcSEcCtD
Mitoxantrone—Anorexia—Sorafenib—thyroid cancer	0.000102	0.0015	CcSEcCtD
Mitoxantrone—Vomiting—Vandetanib—thyroid cancer	0.000101	0.00149	CcSEcCtD
Mitoxantrone—Hyperkalaemia—Doxorubicin—thyroid cancer	0.0001	0.00148	CcSEcCtD
Mitoxantrone—Ecchymosis—Epirubicin—thyroid cancer	9.99e-05	0.00148	CcSEcCtD
Mitoxantrone—Rash—Vandetanib—thyroid cancer	9.97e-05	0.00147	CcSEcCtD
Mitoxantrone—Dermatitis—Vandetanib—thyroid cancer	9.96e-05	0.00147	CcSEcCtD
Mitoxantrone—Headache—Vandetanib—thyroid cancer	9.91e-05	0.00146	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	9.72e-05	0.00144	CcSEcCtD
Mitoxantrone—Blood urea increased—Doxorubicin—thyroid cancer	9.65e-05	0.00143	CcSEcCtD
Mitoxantrone—Sepsis—Epirubicin—thyroid cancer	9.59e-05	0.00142	CcSEcCtD
Mitoxantrone—Dyspnoea—Sorafenib—thyroid cancer	9.51e-05	0.0014	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CDK1—thyroid cancer	9.46e-05	0.00408	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—NRG1—thyroid cancer	9.4e-05	0.00406	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—NRG1—thyroid cancer	9.4e-05	0.00406	CbGpPWpGaD
Mitoxantrone—Nausea—Vandetanib—thyroid cancer	9.39e-05	0.00139	CcSEcCtD
Mitoxantrone—Dyspepsia—Sorafenib—thyroid cancer	9.39e-05	0.00139	CcSEcCtD
Mitoxantrone—Phlebitis—Epirubicin—thyroid cancer	9.31e-05	0.00138	CcSEcCtD
Mitoxantrone—Decreased appetite—Sorafenib—thyroid cancer	9.27e-05	0.00137	CcSEcCtD
Mitoxantrone—Ecchymosis—Doxorubicin—thyroid cancer	9.24e-05	0.00137	CcSEcCtD
Mitoxantrone—Fatigue—Sorafenib—thyroid cancer	9.2e-05	0.00136	CcSEcCtD
Mitoxantrone—BTK—Class I PI3K signaling events—HRAS—thyroid cancer	9.19e-05	0.00397	CbGpPWpGaD
Mitoxantrone—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	9.15e-05	0.00394	CbGpPWpGaD
Mitoxantrone—Constipation—Sorafenib—thyroid cancer	9.12e-05	0.00135	CcSEcCtD
Mitoxantrone—Pain—Sorafenib—thyroid cancer	9.12e-05	0.00135	CcSEcCtD
Mitoxantrone—CYP1B1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	9.12e-05	0.00393	CbGpPWpGaD
Mitoxantrone—ABCB1—trachea—thyroid cancer	9.01e-05	0.0137	CbGeAlD
Mitoxantrone—ABCG2—lymph node—thyroid cancer	8.98e-05	0.0137	CbGeAlD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	8.97e-05	0.00387	CbGpPWpGaD
Mitoxantrone—BTK—IL-5 Signaling Pathway—AKT1—thyroid cancer	8.92e-05	0.00385	CbGpPWpGaD
Mitoxantrone—Sepsis—Doxorubicin—thyroid cancer	8.87e-05	0.00131	CcSEcCtD
Mitoxantrone—Cardiac failure congestive—Epirubicin—thyroid cancer	8.84e-05	0.00131	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Sorafenib—thyroid cancer	8.72e-05	0.00129	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—NRG1—thyroid cancer	8.7e-05	0.00375	CbGpPWpGaD
Mitoxantrone—Renal failure acute—Epirubicin—thyroid cancer	8.69e-05	0.00128	CcSEcCtD
Mitoxantrone—Phlebitis—Doxorubicin—thyroid cancer	8.61e-05	0.00127	CcSEcCtD
Mitoxantrone—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	8.55e-05	0.00369	CbGpPWpGaD
Mitoxantrone—Urticaria—Sorafenib—thyroid cancer	8.47e-05	0.00125	CcSEcCtD
Mitoxantrone—TOP2A—Daunorubicin—Epirubicin—thyroid cancer	8.46e-05	0.0529	CbGdCrCtD
Mitoxantrone—TOP2A—Doxorubicin—Epirubicin—thyroid cancer	8.46e-05	0.0529	CbGdCrCtD
Mitoxantrone—TOP2A—Idarubicin—Epirubicin—thyroid cancer	8.46e-05	0.0529	CbGdCrCtD
Mitoxantrone—Abdominal pain—Sorafenib—thyroid cancer	8.43e-05	0.00125	CcSEcCtD
Mitoxantrone—Body temperature increased—Sorafenib—thyroid cancer	8.43e-05	0.00125	CcSEcCtD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—TP53—thyroid cancer	8.42e-05	0.00363	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—PCM1—thyroid cancer	8.38e-05	0.00361	CbGpPWpGaD
Mitoxantrone—Anaphylactoid reaction—Epirubicin—thyroid cancer	8.29e-05	0.00122	CcSEcCtD
Mitoxantrone—Cardiac failure—Epirubicin—thyroid cancer	8.22e-05	0.00121	CcSEcCtD
Mitoxantrone—Cardiac failure congestive—Doxorubicin—thyroid cancer	8.18e-05	0.00121	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	8.15e-05	0.00351	CbGpPWpGaD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	8.11e-05	0.0035	CbGpPWpGaD
Mitoxantrone—Hyponatraemia—Epirubicin—thyroid cancer	8.05e-05	0.00119	CcSEcCtD
Mitoxantrone—Renal failure acute—Doxorubicin—thyroid cancer	8.04e-05	0.00119	CcSEcCtD
Mitoxantrone—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	8.02e-05	0.00118	CcSEcCtD
Mitoxantrone—Hypersensitivity—Sorafenib—thyroid cancer	7.86e-05	0.00116	CcSEcCtD
Mitoxantrone—BTK—TSLP Signaling Pathway—AKT1—thyroid cancer	7.84e-05	0.00338	CbGpPWpGaD
Mitoxantrone—TOP2A—Idarubicin—Doxorubicin—thyroid cancer	7.83e-05	0.049	CbGdCrCtD
Mitoxantrone—TOP2A—Daunorubicin—Doxorubicin—thyroid cancer	7.83e-05	0.049	CbGdCrCtD
Mitoxantrone—TOP2A—Epirubicin—Doxorubicin—thyroid cancer	7.83e-05	0.049	CbGdCrCtD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—CP—thyroid cancer	7.72e-05	0.00333	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—TPR—thyroid cancer	7.72e-05	0.00333	CbGpPWpGaD
Mitoxantrone—Anaphylactoid reaction—Doxorubicin—thyroid cancer	7.67e-05	0.00113	CcSEcCtD
Mitoxantrone—Asthenia—Sorafenib—thyroid cancer	7.65e-05	0.00113	CcSEcCtD
Mitoxantrone—Cardiac failure—Doxorubicin—thyroid cancer	7.6e-05	0.00112	CcSEcCtD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.6e-05	0.00328	CbGpPWpGaD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.54e-05	0.00325	CbGpPWpGaD
Mitoxantrone—Blood creatinine increased—Epirubicin—thyroid cancer	7.51e-05	0.00111	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—PCM1—thyroid cancer	7.49e-05	0.00323	CbGpPWpGaD
Mitoxantrone—Dehydration—Epirubicin—thyroid cancer	7.46e-05	0.0011	CcSEcCtD
Mitoxantrone—Hyponatraemia—Doxorubicin—thyroid cancer	7.45e-05	0.0011	CcSEcCtD
Mitoxantrone—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	7.42e-05	0.0011	CcSEcCtD
Mitoxantrone—BTK—Kit receptor signaling pathway—HRAS—thyroid cancer	7.4e-05	0.00319	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—TERT—thyroid cancer	7.36e-05	0.00317	CbGpPWpGaD
Mitoxantrone—CYP2E1—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	7.35e-05	0.00317	CbGpPWpGaD
Mitoxantrone—Abdominal pain upper—Epirubicin—thyroid cancer	7.33e-05	0.00108	CcSEcCtD
Mitoxantrone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	7.31e-05	0.00315	CbGpPWpGaD
Mitoxantrone—Hypokalaemia—Epirubicin—thyroid cancer	7.3e-05	0.00108	CcSEcCtD
Mitoxantrone—Diarrhoea—Sorafenib—thyroid cancer	7.3e-05	0.00108	CcSEcCtD
Mitoxantrone—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	7.22e-05	0.00107	CcSEcCtD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—HRAS—thyroid cancer	7.21e-05	0.00311	CbGpPWpGaD
Mitoxantrone—ABCB1—thyroid gland—thyroid cancer	7.13e-05	0.0109	CbGeAlD
Mitoxantrone—Alanine aminotransferase increased—Epirubicin—thyroid cancer	7.07e-05	0.00105	CcSEcCtD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	7.04e-05	0.00304	CbGpPWpGaD
Mitoxantrone—Blood creatinine increased—Doxorubicin—thyroid cancer	6.95e-05	0.00103	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	6.91e-05	0.00298	CbGpPWpGaD
Mitoxantrone—Dehydration—Doxorubicin—thyroid cancer	6.9e-05	0.00102	CcSEcCtD
Mitoxantrone—BTK—Immune System—RAP1GAP—thyroid cancer	6.81e-05	0.00294	CbGpPWpGaD
Mitoxantrone—Vomiting—Sorafenib—thyroid cancer	6.78e-05	0.001	CcSEcCtD
Mitoxantrone—Abdominal pain upper—Doxorubicin—thyroid cancer	6.78e-05	0.001	CcSEcCtD
Mitoxantrone—Hypokalaemia—Doxorubicin—thyroid cancer	6.75e-05	0.000998	CcSEcCtD
Mitoxantrone—Rash—Sorafenib—thyroid cancer	6.73e-05	0.000994	CcSEcCtD
Mitoxantrone—Dermatitis—Sorafenib—thyroid cancer	6.72e-05	0.000993	CcSEcCtD
Mitoxantrone—BTK—BCR signaling pathway—HRAS—thyroid cancer	6.69e-05	0.00288	CbGpPWpGaD
Mitoxantrone—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	6.68e-05	0.000987	CcSEcCtD
Mitoxantrone—Headache—Sorafenib—thyroid cancer	6.68e-05	0.000987	CcSEcCtD
Mitoxantrone—ABCC1—Arachidonic acid metabolism—PTGS2—thyroid cancer	6.68e-05	0.00288	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—LGALS3—thyroid cancer	6.66e-05	0.00287	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	6.65e-05	0.00287	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—PRKAR1A—thyroid cancer	6.61e-05	0.00285	CbGpPWpGaD
Mitoxantrone—Pancytopenia—Epirubicin—thyroid cancer	6.58e-05	0.000973	CcSEcCtD
Mitoxantrone—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	6.55e-05	0.000967	CcSEcCtD
Mitoxantrone—BTK—Kit receptor signaling pathway—AKT1—thyroid cancer	6.54e-05	0.00282	CbGpPWpGaD
Mitoxantrone—Neutropenia—Epirubicin—thyroid cancer	6.48e-05	0.000958	CcSEcCtD
Mitoxantrone—CYP1B1—Arachidonic acid metabolism—PTGS2—thyroid cancer	6.46e-05	0.00279	CbGpPWpGaD
Mitoxantrone—Upper respiratory tract infection—Epirubicin—thyroid cancer	6.44e-05	0.000952	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	6.39e-05	0.00276	CbGpPWpGaD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—AKT1—thyroid cancer	6.36e-05	0.00274	CbGpPWpGaD
Mitoxantrone—Nausea—Sorafenib—thyroid cancer	6.34e-05	0.000936	CcSEcCtD
Mitoxantrone—ABCB1—head—thyroid cancer	6.32e-05	0.00963	CbGeAlD
Mitoxantrone—Weight increased—Epirubicin—thyroid cancer	6.31e-05	0.000932	CcSEcCtD
Mitoxantrone—Weight decreased—Epirubicin—thyroid cancer	6.27e-05	0.000927	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Epirubicin—thyroid cancer	6.25e-05	0.000924	CcSEcCtD
Mitoxantrone—Pneumonia—Epirubicin—thyroid cancer	6.22e-05	0.000918	CcSEcCtD
Mitoxantrone—Drowsiness—Epirubicin—thyroid cancer	6.18e-05	0.000913	CcSEcCtD
Mitoxantrone—Pancytopenia—Doxorubicin—thyroid cancer	6.09e-05	0.0009	CcSEcCtD
Mitoxantrone—Renal failure—Epirubicin—thyroid cancer	6.08e-05	0.000898	CcSEcCtD
Mitoxantrone—Jaundice—Epirubicin—thyroid cancer	6.03e-05	0.00089	CcSEcCtD
Mitoxantrone—Stomatitis—Epirubicin—thyroid cancer	6.03e-05	0.00089	CcSEcCtD
Mitoxantrone—Urinary tract infection—Epirubicin—thyroid cancer	6.01e-05	0.000888	CcSEcCtD
Mitoxantrone—Conjunctivitis—Epirubicin—thyroid cancer	6.01e-05	0.000888	CcSEcCtD
Mitoxantrone—Neutropenia—Doxorubicin—thyroid cancer	6e-05	0.000886	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Doxorubicin—thyroid cancer	5.96e-05	0.000881	CcSEcCtD
Mitoxantrone—CYP2E1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	5.95e-05	0.00257	CbGpPWpGaD
Mitoxantrone—Sweating—Epirubicin—thyroid cancer	5.93e-05	0.000875	CcSEcCtD
Mitoxantrone—BTK—BCR signaling pathway—AKT1—thyroid cancer	5.9e-05	0.00255	CbGpPWpGaD
Mitoxantrone—Haematuria—Epirubicin—thyroid cancer	5.89e-05	0.000871	CcSEcCtD
Mitoxantrone—Weight increased—Doxorubicin—thyroid cancer	5.84e-05	0.000862	CcSEcCtD
Mitoxantrone—Weight decreased—Doxorubicin—thyroid cancer	5.8e-05	0.000857	CcSEcCtD
Mitoxantrone—Sinusitis—Epirubicin—thyroid cancer	5.8e-05	0.000857	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Doxorubicin—thyroid cancer	5.79e-05	0.000855	CcSEcCtD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.78e-05	0.00249	CbGpPWpGaD
Mitoxantrone—Agranulocytosis—Epirubicin—thyroid cancer	5.77e-05	0.000852	CcSEcCtD
Mitoxantrone—Pneumonia—Doxorubicin—thyroid cancer	5.75e-05	0.00085	CcSEcCtD
Mitoxantrone—Drowsiness—Doxorubicin—thyroid cancer	5.72e-05	0.000845	CcSEcCtD
Mitoxantrone—Bradycardia—Epirubicin—thyroid cancer	5.65e-05	0.000835	CcSEcCtD
Mitoxantrone—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	5.63e-05	0.00243	CbGpPWpGaD
Mitoxantrone—Renal failure—Doxorubicin—thyroid cancer	5.62e-05	0.000831	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	5.6e-05	0.00242	CbGpPWpGaD
Mitoxantrone—Haemoglobin—Epirubicin—thyroid cancer	5.58e-05	0.000824	CcSEcCtD
Mitoxantrone—Jaundice—Doxorubicin—thyroid cancer	5.57e-05	0.000824	CcSEcCtD
Mitoxantrone—Stomatitis—Doxorubicin—thyroid cancer	5.57e-05	0.000824	CcSEcCtD
Mitoxantrone—Rhinitis—Epirubicin—thyroid cancer	5.56e-05	0.000822	CcSEcCtD
Mitoxantrone—Conjunctivitis—Doxorubicin—thyroid cancer	5.56e-05	0.000821	CcSEcCtD
Mitoxantrone—Urinary tract infection—Doxorubicin—thyroid cancer	5.56e-05	0.000821	CcSEcCtD
Mitoxantrone—Haemorrhage—Epirubicin—thyroid cancer	5.55e-05	0.00082	CcSEcCtD
Mitoxantrone—Hepatitis—Epirubicin—thyroid cancer	5.55e-05	0.00082	CcSEcCtD
Mitoxantrone—Pharyngitis—Epirubicin—thyroid cancer	5.51e-05	0.000814	CcSEcCtD
Mitoxantrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	5.5e-05	0.00237	CbGpPWpGaD
Mitoxantrone—Sweating—Doxorubicin—thyroid cancer	5.48e-05	0.00081	CcSEcCtD
Mitoxantrone—Haematuria—Doxorubicin—thyroid cancer	5.45e-05	0.000806	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	5.37e-05	0.00232	CbGpPWpGaD
Mitoxantrone—Sinusitis—Doxorubicin—thyroid cancer	5.37e-05	0.000793	CcSEcCtD
Mitoxantrone—Agranulocytosis—Doxorubicin—thyroid cancer	5.34e-05	0.000788	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	5.32e-05	0.0023	CbGpPWpGaD
Mitoxantrone—Bradycardia—Doxorubicin—thyroid cancer	5.23e-05	0.000772	CcSEcCtD
Mitoxantrone—Haemoglobin—Doxorubicin—thyroid cancer	5.16e-05	0.000762	CcSEcCtD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	5.15e-05	0.00222	CbGpPWpGaD
Mitoxantrone—Rhinitis—Doxorubicin—thyroid cancer	5.15e-05	0.00076	CcSEcCtD
Mitoxantrone—Hepatitis—Doxorubicin—thyroid cancer	5.13e-05	0.000759	CcSEcCtD
Mitoxantrone—Haemorrhage—Doxorubicin—thyroid cancer	5.13e-05	0.000759	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—TPR—thyroid cancer	5.12e-05	0.00221	CbGpPWpGaD
Mitoxantrone—Pharyngitis—Doxorubicin—thyroid cancer	5.1e-05	0.000753	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—PTEN—thyroid cancer	5.01e-05	0.00216	CbGpPWpGaD
Mitoxantrone—Chills—Epirubicin—thyroid cancer	4.98e-05	0.000736	CcSEcCtD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—HRAS—thyroid cancer	4.97e-05	0.00214	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	4.97e-05	0.00214	CbGpPWpGaD
Mitoxantrone—Arrhythmia—Epirubicin—thyroid cancer	4.96e-05	0.000732	CcSEcCtD
Mitoxantrone—Alopecia—Epirubicin—thyroid cancer	4.9e-05	0.000724	CcSEcCtD
Mitoxantrone—ABCG2—Fluoropyrimidine Activity—TP53—thyroid cancer	4.88e-05	0.0021	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.86e-05	0.00209	CbGpPWpGaD
Mitoxantrone—CYP1B1—Biological oxidations—RXRA—thyroid cancer	4.84e-05	0.00209	CbGpPWpGaD
Mitoxantrone—Erythema—Epirubicin—thyroid cancer	4.83e-05	0.000714	CcSEcCtD
Mitoxantrone—Dysgeusia—Epirubicin—thyroid cancer	4.73e-05	0.000699	CcSEcCtD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—PTEN—thyroid cancer	4.71e-05	0.00203	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—PTEN—thyroid cancer	4.71e-05	0.00203	CbGpPWpGaD
Mitoxantrone—Back pain—Epirubicin—thyroid cancer	4.67e-05	0.00069	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	4.63e-05	0.002	CbGpPWpGaD
Mitoxantrone—Chills—Doxorubicin—thyroid cancer	4.61e-05	0.000681	CcSEcCtD
Mitoxantrone—Arrhythmia—Doxorubicin—thyroid cancer	4.59e-05	0.000678	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—TPR—thyroid cancer	4.58e-05	0.00197	CbGpPWpGaD
Mitoxantrone—Vision blurred—Epirubicin—thyroid cancer	4.55e-05	0.000673	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—CDK1—thyroid cancer	4.55e-05	0.00196	CbGpPWpGaD
Mitoxantrone—Alopecia—Doxorubicin—thyroid cancer	4.54e-05	0.00067	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Epirubicin—thyroid cancer	4.48e-05	0.000662	CcSEcCtD
Mitoxantrone—Erythema—Doxorubicin—thyroid cancer	4.47e-05	0.00066	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—NRAS—thyroid cancer	4.47e-05	0.00193	CbGpPWpGaD
Mitoxantrone—Anaemia—Epirubicin—thyroid cancer	4.46e-05	0.00066	CcSEcCtD
Mitoxantrone—ABCB1—lymph node—thyroid cancer	4.43e-05	0.00675	CbGeAlD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—AKT1—thyroid cancer	4.39e-05	0.00189	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—IFNA2—thyroid cancer	4.38e-05	0.00189	CbGpPWpGaD
Mitoxantrone—Dysgeusia—Doxorubicin—thyroid cancer	4.38e-05	0.000647	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—PTEN—thyroid cancer	4.36e-05	0.00188	CbGpPWpGaD
Mitoxantrone—Malaise—Epirubicin—thyroid cancer	4.36e-05	0.000644	CcSEcCtD
Mitoxantrone—Leukopenia—Epirubicin—thyroid cancer	4.32e-05	0.000639	CcSEcCtD
Mitoxantrone—Back pain—Doxorubicin—thyroid cancer	4.32e-05	0.000639	CcSEcCtD
Mitoxantrone—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—thyroid cancer	4.29e-05	0.00185	CbGpPWpGaD
Mitoxantrone—Cough—Epirubicin—thyroid cancer	4.22e-05	0.000623	CcSEcCtD
Mitoxantrone—Vision blurred—Doxorubicin—thyroid cancer	4.21e-05	0.000622	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—NRAS—thyroid cancer	4.2e-05	0.00181	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—NRAS—thyroid cancer	4.2e-05	0.00181	CbGpPWpGaD
Mitoxantrone—Convulsion—Epirubicin—thyroid cancer	4.19e-05	0.000618	CcSEcCtD
Mitoxantrone—Hypertension—Epirubicin—thyroid cancer	4.17e-05	0.000616	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Doxorubicin—thyroid cancer	4.15e-05	0.000613	CcSEcCtD
Mitoxantrone—Anaemia—Doxorubicin—thyroid cancer	4.13e-05	0.00061	CcSEcCtD
Mitoxantrone—Myalgia—Epirubicin—thyroid cancer	4.11e-05	0.000608	CcSEcCtD
Mitoxantrone—Chest pain—Epirubicin—thyroid cancer	4.11e-05	0.000608	CcSEcCtD
Mitoxantrone—Arthralgia—Epirubicin—thyroid cancer	4.11e-05	0.000608	CcSEcCtD
Mitoxantrone—Anxiety—Epirubicin—thyroid cancer	4.1e-05	0.000605	CcSEcCtD
Mitoxantrone—Discomfort—Epirubicin—thyroid cancer	4.06e-05	0.0006	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—PPARG—thyroid cancer	4.03e-05	0.00174	CbGpPWpGaD
Mitoxantrone—Malaise—Doxorubicin—thyroid cancer	4.03e-05	0.000595	CcSEcCtD
Mitoxantrone—Leukopenia—Doxorubicin—thyroid cancer	4e-05	0.000591	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	3.98e-05	0.00172	CbGpPWpGaD
Mitoxantrone—Confusional state—Epirubicin—thyroid cancer	3.98e-05	0.000587	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Epirubicin—thyroid cancer	3.94e-05	0.000582	CcSEcCtD
Mitoxantrone—Oedema—Epirubicin—thyroid cancer	3.94e-05	0.000582	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CCND1—thyroid cancer	3.94e-05	0.0017	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	3.93e-05	0.0017	CbGpPWpGaD
Mitoxantrone—Infection—Epirubicin—thyroid cancer	3.92e-05	0.000579	CcSEcCtD
Mitoxantrone—BTK—Immune System—TPR—thyroid cancer	3.91e-05	0.00169	CbGpPWpGaD
Mitoxantrone—Cough—Doxorubicin—thyroid cancer	3.9e-05	0.000576	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—NRAS—thyroid cancer	3.89e-05	0.00168	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—LGALS3—thyroid cancer	3.88e-05	0.00167	CbGpPWpGaD
Mitoxantrone—Shock—Epirubicin—thyroid cancer	3.88e-05	0.000573	CcSEcCtD
Mitoxantrone—Convulsion—Doxorubicin—thyroid cancer	3.87e-05	0.000572	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Epirubicin—thyroid cancer	3.86e-05	0.00057	CcSEcCtD
Mitoxantrone—Hypertension—Doxorubicin—thyroid cancer	3.86e-05	0.00057	CcSEcCtD
Mitoxantrone—BTK—Immune System—PRKAR1A—thyroid cancer	3.85e-05	0.00166	CbGpPWpGaD
Mitoxantrone—Tachycardia—Epirubicin—thyroid cancer	3.85e-05	0.000568	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—KRAS—thyroid cancer	3.84e-05	0.00166	CbGpPWpGaD
Mitoxantrone—Skin disorder—Epirubicin—thyroid cancer	3.83e-05	0.000566	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Epirubicin—thyroid cancer	3.81e-05	0.000563	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	3.81e-05	0.00164	CbGpPWpGaD
Mitoxantrone—Arthralgia—Doxorubicin—thyroid cancer	3.81e-05	0.000562	CcSEcCtD
Mitoxantrone—Chest pain—Doxorubicin—thyroid cancer	3.81e-05	0.000562	CcSEcCtD
Mitoxantrone—Myalgia—Doxorubicin—thyroid cancer	3.81e-05	0.000562	CcSEcCtD
Mitoxantrone—Anxiety—Doxorubicin—thyroid cancer	3.79e-05	0.00056	CcSEcCtD
Mitoxantrone—Discomfort—Doxorubicin—thyroid cancer	3.76e-05	0.000555	CcSEcCtD
Mitoxantrone—Anorexia—Epirubicin—thyroid cancer	3.76e-05	0.000555	CcSEcCtD
Mitoxantrone—ABCC1—Disease—TRIM24—thyroid cancer	3.73e-05	0.00161	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	3.69e-05	0.00159	CbGpPWpGaD
Mitoxantrone—Hypotension—Epirubicin—thyroid cancer	3.68e-05	0.000544	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—MINPP1—thyroid cancer	3.68e-05	0.00159	CbGpPWpGaD
Mitoxantrone—Confusional state—Doxorubicin—thyroid cancer	3.68e-05	0.000543	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—NRG1—thyroid cancer	3.65e-05	0.00158	CbGpPWpGaD
Mitoxantrone—Anaphylactic shock—Doxorubicin—thyroid cancer	3.65e-05	0.000539	CcSEcCtD
Mitoxantrone—Oedema—Doxorubicin—thyroid cancer	3.65e-05	0.000539	CcSEcCtD
Mitoxantrone—Infection—Doxorubicin—thyroid cancer	3.62e-05	0.000535	CcSEcCtD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—KRAS—thyroid cancer	3.62e-05	0.00156	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—KRAS—thyroid cancer	3.62e-05	0.00156	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	3.59e-05	0.000531	CcSEcCtD
Mitoxantrone—Shock—Doxorubicin—thyroid cancer	3.59e-05	0.00053	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Doxorubicin—thyroid cancer	3.57e-05	0.000528	CcSEcCtD
Mitoxantrone—Tachycardia—Doxorubicin—thyroid cancer	3.56e-05	0.000526	CcSEcCtD
Mitoxantrone—CYP1B1—Metabolism—MINPP1—thyroid cancer	3.56e-05	0.00153	CbGpPWpGaD
Mitoxantrone—Skin disorder—Doxorubicin—thyroid cancer	3.54e-05	0.000523	CcSEcCtD
Mitoxantrone—Paraesthesia—Epirubicin—thyroid cancer	3.54e-05	0.000523	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Doxorubicin—thyroid cancer	3.53e-05	0.000521	CcSEcCtD
Mitoxantrone—Dyspnoea—Epirubicin—thyroid cancer	3.51e-05	0.000519	CcSEcCtD
Mitoxantrone—ABCC1—Disease—CHST14—thyroid cancer	3.51e-05	0.00151	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—NRG1—thyroid cancer	3.51e-05	0.00151	CbGpPWpGaD
Mitoxantrone—Somnolence—Epirubicin—thyroid cancer	3.5e-05	0.000518	CcSEcCtD
Mitoxantrone—Anorexia—Doxorubicin—thyroid cancer	3.48e-05	0.000514	CcSEcCtD
Mitoxantrone—Dyspepsia—Epirubicin—thyroid cancer	3.47e-05	0.000513	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDK1—thyroid cancer	3.47e-05	0.0015	CbGpPWpGaD
Mitoxantrone—Decreased appetite—Epirubicin—thyroid cancer	3.43e-05	0.000506	CcSEcCtD
Mitoxantrone—Hypotension—Doxorubicin—thyroid cancer	3.41e-05	0.000504	CcSEcCtD
Mitoxantrone—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	3.41e-05	0.00147	CbGpPWpGaD
Mitoxantrone—Fatigue—Epirubicin—thyroid cancer	3.4e-05	0.000502	CcSEcCtD
Mitoxantrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	3.39e-05	0.00146	CbGpPWpGaD
Mitoxantrone—Constipation—Epirubicin—thyroid cancer	3.37e-05	0.000498	CcSEcCtD
Mitoxantrone—Pain—Epirubicin—thyroid cancer	3.37e-05	0.000498	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—KRAS—thyroid cancer	3.35e-05	0.00144	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TRIM33—thyroid cancer	3.33e-05	0.00144	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	3.32e-05	0.000491	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	3.3e-05	0.00142	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—AKT1—thyroid cancer	3.29e-05	0.00142	CbGpPWpGaD
Mitoxantrone—Paraesthesia—Doxorubicin—thyroid cancer	3.28e-05	0.000484	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—HRAS—thyroid cancer	3.27e-05	0.00141	CbGpPWpGaD
Mitoxantrone—Dyspnoea—Doxorubicin—thyroid cancer	3.25e-05	0.00048	CcSEcCtD
Mitoxantrone—Feeling abnormal—Epirubicin—thyroid cancer	3.25e-05	0.00048	CcSEcCtD
Mitoxantrone—Somnolence—Doxorubicin—thyroid cancer	3.24e-05	0.000479	CcSEcCtD
Mitoxantrone—ABCG2—Metabolism—MINPP1—thyroid cancer	3.24e-05	0.0014	CbGpPWpGaD
Mitoxantrone—Gastrointestinal pain—Epirubicin—thyroid cancer	3.22e-05	0.000476	CcSEcCtD
Mitoxantrone—Dyspepsia—Doxorubicin—thyroid cancer	3.21e-05	0.000474	CcSEcCtD
Mitoxantrone—Decreased appetite—Doxorubicin—thyroid cancer	3.17e-05	0.000468	CcSEcCtD
Mitoxantrone—CYP2E1—Biological oxidations—RXRA—thyroid cancer	3.16e-05	0.00136	CbGpPWpGaD
Mitoxantrone—Fatigue—Doxorubicin—thyroid cancer	3.14e-05	0.000465	CcSEcCtD
Mitoxantrone—Urticaria—Epirubicin—thyroid cancer	3.13e-05	0.000463	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—NDUFA13—thyroid cancer	3.13e-05	0.00135	CbGpPWpGaD
Mitoxantrone—Pain—Doxorubicin—thyroid cancer	3.12e-05	0.000461	CcSEcCtD
Mitoxantrone—Constipation—Doxorubicin—thyroid cancer	3.12e-05	0.000461	CcSEcCtD
Mitoxantrone—Abdominal pain—Epirubicin—thyroid cancer	3.12e-05	0.00046	CcSEcCtD
Mitoxantrone—Body temperature increased—Epirubicin—thyroid cancer	3.12e-05	0.00046	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—CDK1—thyroid cancer	3.1e-05	0.00134	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—HRAS—thyroid cancer	3.07e-05	0.00133	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	3.07e-05	0.00133	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—NDUFA13—thyroid cancer	3.02e-05	0.0013	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Doxorubicin—thyroid cancer	3.01e-05	0.000444	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	2.99e-05	0.00129	CbGpPWpGaD
Mitoxantrone—Gastrointestinal pain—Doxorubicin—thyroid cancer	2.98e-05	0.000441	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—CHST14—thyroid cancer	2.94e-05	0.00127	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—TPR—thyroid cancer	2.91e-05	0.00125	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—CP—thyroid cancer	2.91e-05	0.00125	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Epirubicin—thyroid cancer	2.9e-05	0.000429	CcSEcCtD
Mitoxantrone—Urticaria—Doxorubicin—thyroid cancer	2.9e-05	0.000428	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—AKT1—thyroid cancer	2.89e-05	0.00124	CbGpPWpGaD
Mitoxantrone—Abdominal pain—Doxorubicin—thyroid cancer	2.88e-05	0.000426	CcSEcCtD
Mitoxantrone—Body temperature increased—Doxorubicin—thyroid cancer	2.88e-05	0.000426	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.88e-05	0.00124	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	2.86e-05	0.00123	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—HRAS—thyroid cancer	2.84e-05	0.00123	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—CHST14—thyroid cancer	2.84e-05	0.00123	CbGpPWpGaD
Mitoxantrone—Asthenia—Epirubicin—thyroid cancer	2.83e-05	0.000418	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—PTEN—thyroid cancer	2.77e-05	0.00119	CbGpPWpGaD
Mitoxantrone—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	2.76e-05	0.00119	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—NDUFA13—thyroid cancer	2.75e-05	0.00119	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—AKT1—thyroid cancer	2.71e-05	0.00117	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	2.71e-05	0.00117	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Epirubicin—thyroid cancer	2.7e-05	0.000398	CcSEcCtD
Mitoxantrone—Hypersensitivity—Doxorubicin—thyroid cancer	2.69e-05	0.000397	CcSEcCtD
Mitoxantrone—BTK—Immune System—CDK1—thyroid cancer	2.65e-05	0.00114	CbGpPWpGaD
Mitoxantrone—Asthenia—Doxorubicin—thyroid cancer	2.62e-05	0.000387	CcSEcCtD
Mitoxantrone—ABCG2—Metabolism—CHST14—thyroid cancer	2.59e-05	0.00112	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—TPR—thyroid cancer	2.56e-05	0.0011	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—CP—thyroid cancer	2.56e-05	0.0011	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IFNA2—thyroid cancer	2.55e-05	0.0011	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	2.52e-05	0.00109	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—AKT1—thyroid cancer	2.51e-05	0.00108	CbGpPWpGaD
Mitoxantrone—Vomiting—Epirubicin—thyroid cancer	2.51e-05	0.00037	CcSEcCtD
Mitoxantrone—Diarrhoea—Doxorubicin—thyroid cancer	2.5e-05	0.000369	CcSEcCtD
Mitoxantrone—Rash—Epirubicin—thyroid cancer	2.49e-05	0.000367	CcSEcCtD
Mitoxantrone—Dermatitis—Epirubicin—thyroid cancer	2.48e-05	0.000367	CcSEcCtD
Mitoxantrone—Headache—Epirubicin—thyroid cancer	2.47e-05	0.000365	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—HPGD—thyroid cancer	2.37e-05	0.00102	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	2.37e-05	0.00102	CbGpPWpGaD
Mitoxantrone—Nausea—Epirubicin—thyroid cancer	2.34e-05	0.000346	CcSEcCtD
Mitoxantrone—CYP2E1—Metabolism—MINPP1—thyroid cancer	2.32e-05	0.001	CbGpPWpGaD
Mitoxantrone—Vomiting—Doxorubicin—thyroid cancer	2.32e-05	0.000343	CcSEcCtD
Mitoxantrone—Rash—Doxorubicin—thyroid cancer	2.3e-05	0.00034	CcSEcCtD
Mitoxantrone—Dermatitis—Doxorubicin—thyroid cancer	2.3e-05	0.000339	CcSEcCtD
Mitoxantrone—CYP1B1—Metabolism—HPGD—thyroid cancer	2.29e-05	0.000989	CbGpPWpGaD
Mitoxantrone—Headache—Doxorubicin—thyroid cancer	2.29e-05	0.000338	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—TERT—thyroid cancer	2.24e-05	0.000964	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TCF7L1—thyroid cancer	2.22e-05	0.000958	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.21e-05	0.000954	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	2.19e-05	0.000945	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	2.18e-05	0.000938	CbGpPWpGaD
Mitoxantrone—Nausea—Doxorubicin—thyroid cancer	2.17e-05	0.00032	CcSEcCtD
Mitoxantrone—BTK—Immune System—NRG1—thyroid cancer	2.13e-05	0.000918	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—HPGD—thyroid cancer	2.09e-05	0.000899	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—NDUFA13—thyroid cancer	1.98e-05	0.000852	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.97e-05	0.000848	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.92e-05	0.000829	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.91e-05	0.000826	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TP53—thyroid cancer	1.89e-05	0.000814	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.86e-05	0.000802	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CHST14—thyroid cancer	1.86e-05	0.000801	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—PTEN—thyroid cancer	1.83e-05	0.000789	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.83e-05	0.000788	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—PTEN—thyroid cancer	1.76e-05	0.000758	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—MINPP1—thyroid cancer	1.75e-05	0.000755	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.66e-05	0.000716	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—NRAS—thyroid cancer	1.63e-05	0.000704	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TPR—thyroid cancer	1.63e-05	0.000701	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.61e-05	0.000694	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PRKAR1A—thyroid cancer	1.6e-05	0.00069	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—NRAS—thyroid cancer	1.57e-05	0.000676	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MEN1—thyroid cancer	1.53e-05	0.000659	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—HPGD—thyroid cancer	1.5e-05	0.000646	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—NDUFA13—thyroid cancer	1.49e-05	0.000642	CbGpPWpGaD
Mitoxantrone—CYP3A4—Biological oxidations—RXRA—thyroid cancer	1.47e-05	0.000633	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CCND1—thyroid cancer	1.45e-05	0.000623	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—KRAS—thyroid cancer	1.41e-05	0.000606	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CHST14—thyroid cancer	1.4e-05	0.000603	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	1.38e-05	0.000596	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	1.38e-05	0.000596	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—TPR—thyroid cancer	1.36e-05	0.000587	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	1.36e-05	0.000587	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—KRAS—thyroid cancer	1.35e-05	0.000582	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PRKAR1A—thyroid cancer	1.34e-05	0.000578	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—TPR—thyroid cancer	1.32e-05	0.000568	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PRKAR1A—thyroid cancer	1.3e-05	0.000559	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CCND1—thyroid cancer	1.29e-05	0.000557	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	1.28e-05	0.000552	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CALCA—thyroid cancer	1.22e-05	0.000525	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.21e-05	0.000524	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—TPR—thyroid cancer	1.2e-05	0.000517	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—HRAS—thyroid cancer	1.19e-05	0.000515	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PRKAR1A—thyroid cancer	1.18e-05	0.000508	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.17e-05	0.000506	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—HRAS—thyroid cancer	1.15e-05	0.000495	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—HPGD—thyroid cancer	1.13e-05	0.000486	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CDK1—thyroid cancer	1.1e-05	0.000475	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	1.09e-05	0.000469	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—MINPP1—thyroid cancer	1.08e-05	0.000465	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—PTEN—thyroid cancer	1.07e-05	0.00046	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—AKT1—thyroid cancer	1.05e-05	0.000455	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.04e-05	0.000446	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—SLC5A5—thyroid cancer	1.02e-05	0.00044	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—AKT1—thyroid cancer	1.01e-05	0.000437	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—SLC5A5—thyroid cancer	9.86e-06	0.000425	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	9.83e-06	0.000424	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	9.55e-06	0.000412	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—NRAS—thyroid cancer	9.51e-06	0.00041	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	9.49e-06	0.000409	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	9.24e-06	0.000398	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—NDUFA13—thyroid cancer	9.17e-06	0.000395	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—SLC5A5—thyroid cancer	8.97e-06	0.000387	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—NRG1—thyroid cancer	8.84e-06	0.000381	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	8.7e-06	0.000375	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—CHST14—thyroid cancer	8.62e-06	0.000372	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—TPR—thyroid cancer	8.6e-06	0.000371	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—RXRA—thyroid cancer	8.56e-06	0.000369	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TP53—thyroid cancer	8.51e-06	0.000367	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PRKAR1A—thyroid cancer	8.46e-06	0.000365	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.33e-06	0.000359	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—RXRA—thyroid cancer	8.28e-06	0.000357	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—KRAS—thyroid cancer	8.18e-06	0.000353	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.05e-06	0.000347	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TERT—thyroid cancer	7.94e-06	0.000342	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HIF1A—thyroid cancer	7.59e-06	0.000327	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—RXRA—thyroid cancer	7.53e-06	0.000325	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	7.29e-06	0.000314	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—HRAS—thyroid cancer	6.96e-06	0.0003	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—HPGD—thyroid cancer	6.95e-06	0.0003	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—TPR—thyroid cancer	6.48e-06	0.000279	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	6.48e-06	0.000279	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—SLC5A5—thyroid cancer	6.44e-06	0.000278	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PRKAR1A—thyroid cancer	6.37e-06	0.000275	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—BRAF—thyroid cancer	6.29e-06	0.000271	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—AKT1—thyroid cancer	6.14e-06	0.000265	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	5.47e-06	0.000236	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—RXRA—thyroid cancer	5.41e-06	0.000233	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PPARG—thyroid cancer	5.41e-06	0.000233	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PPARG—thyroid cancer	5.23e-06	0.000226	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PTGS2—thyroid cancer	5.08e-06	0.000219	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—SLC5A5—thyroid cancer	4.85e-06	0.000209	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PPARG—thyroid cancer	4.76e-06	0.000205	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PTEN—thyroid cancer	4.43e-06	0.000191	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PTGS2—thyroid cancer	4.25e-06	0.000183	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PTGS2—thyroid cancer	4.11e-06	0.000177	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—RXRA—thyroid cancer	4.07e-06	0.000176	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—TPR—thyroid cancer	3.99e-06	0.000172	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—NRAS—thyroid cancer	3.95e-06	0.00017	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.93e-06	0.000169	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PTGS2—thyroid cancer	3.74e-06	0.000161	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PTEN—thyroid cancer	3.71e-06	0.00016	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PTEN—thyroid cancer	3.59e-06	0.000155	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PPARG—thyroid cancer	3.42e-06	0.000147	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—KRAS—thyroid cancer	3.4e-06	0.000147	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PTEN—thyroid cancer	3.26e-06	0.000141	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.99e-06	0.000129	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HRAS—thyroid cancer	2.89e-06	0.000125	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PTGS2—thyroid cancer	2.69e-06	0.000116	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PPARG—thyroid cancer	2.57e-06	0.000111	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—AKT1—thyroid cancer	2.55e-06	0.00011	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—RXRA—thyroid cancer	2.51e-06	0.000108	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PTEN—thyroid cancer	2.34e-06	0.000101	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—AKT1—thyroid cancer	2.14e-06	9.22e-05	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—AKT1—thyroid cancer	2.07e-06	8.92e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PTGS2—thyroid cancer	2.02e-06	8.73e-05	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—AKT1—thyroid cancer	1.88e-06	8.11e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PTEN—thyroid cancer	1.76e-06	7.61e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PPARG—thyroid cancer	1.58e-06	6.83e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—AKT1—thyroid cancer	1.35e-06	5.82e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.25e-06	5.38e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PTEN—thyroid cancer	1.09e-06	4.69e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—AKT1—thyroid cancer	1.02e-06	4.39e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—AKT1—thyroid cancer	6.26e-07	2.7e-05	CbGpPWpGaD
